Genitourinary Cancers | Specialty

Treating Oligometastatic Renal Cell Carcinoma

July 21st 2015

Immunotherapy Combinations in Renal Cell Carcinoma

July 21st 2015

PD-1 Inhibition in Advanced Renal Cell Carcinoma

July 21st 2015

Nivolumab Improves Survival in Phase III RCC Trial

July 20th 2015

The phase III CheckMate-025 trial has been halted after an independent panel determined that nivolumab improved overall survival versus everolimus in patients with advanced renal cell carcinoma.

Second-Line Cabozantinib Improves OS, PFS in mRCC

July 20th 2015

Treatment with cabozantinib improved progression-free survival and overall survival compared with everolimus in pretreated patients with metastatic renal cell carcinoma.

Gefitinib Approved for NSCLC, Atezolizumab Shrinks Bladder Tumors, and More

July 19th 2015

Dr. Figlin on Ongoing ADAPT Trial for mRCC

July 14th 2015

Robert Figlin, MD, FACP, professor of Medicine and Biomedical Sciences, Steven Spielberg Family Chair in Hematology Oncology, director, Division of Hematology Oncology, deputy director, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai, discusses the ongoing phase III ADAPT trial, which examines AGS-003 combined with sunitinib for the treatment of patients with mRCC.

Atezolizumab Achieves Primary Endpoint in Pivotal Phase II Bladder Cancer Study

July 13th 2015

Second-line treatment with atezolizumab (MPDL3280A) has met the primary endpoint of a pivotal phase II study by effectively shrinking tumors in patients with locally advanced or metastatic urothelial bladder cancer.

Dr. Feldman on Link Between Obesity and Risk for RCC

July 9th 2015

Adam S. Feldman, MD, MPH, urologist, Department of Urology, Massachusetts General Hospital, discusses the association between obesity and the risk of developing total and fatal renal cell carcinoma (RCC).

Case Studies Offer Window Into Evolving Prostate Cancer Paradigm

July 9th 2015

Although guideline organizations have now incorporated the results of major clinical trials into treatment paradigms, much controversy remains over how best to sequence therapies in prostate cancer.

Dr. Voss on Bevacizumab With CRLX101 in Advanced RCC

June 25th 2015

Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses a phase II study examining bevacizumab combined with CRLX101 in patients with advanced renal cell carcinoma.

Grasp of Clinical Science Now a Necessity in Urologic Oncology

June 17th 2015

The world of precision medicine is upon us and we as providers, especially those involved in the management of oncology patients, will need to be conversant and have an understanding of these various pathways and drivers in order to more effectively manage our patients

Specialty Pharmacy Makes Inroads in Urology Practice

June 10th 2015

There are many processes for a urology practice to consider when partnering with a specialty pharmacy, including time and capital investments.

Lenvatinib Plus Everolimus Improves Survival in mRCC

June 5th 2015

The combination of lenvatinib and everolimus more than doubled progression-free survival and extended overall survival by 10.1 months compared with everolimus alone as a second-line treatment for patients with metastatic renal cell carcinoma.

Progress in Immunotherapy Continues, But Pseudo-Progression Is a Concern

June 5th 2015

Interest is high among urologists and medical oncologists with "the explosion of checkpoint blockade inhibition studies" that initially made inroads in melanoma and non-small cell lung cancer, but is also gaining traction in bladder cancer.

Simple Urine Biomarker Test Could Identify Early-Stage Renal Cell Carcinoma

June 4th 2015

Two urine biomarkers, aquaporin 1 and perilipin 2, could be the key to the development of a simple urine test that leads to the detection of asymptomatic, early-stage kidney cancer.

Dr. Petrylak on the Future Immunotherapy in Bladder Cancer

May 27th 2015

Daniel Petrylak, MD, Professor of Medicine and of Urology; Professor, Signal Transduction Research Program at Yale Cancer Center discusses the future of immunotherapy in bladder cancer.

Pembrolizumab Active in Advanced Urothelial Cancer

May 19th 2015

A fourth of patients with advanced urothelial cancer had objective responses to treatment with the immune checkpoint inhibitor pembrolizumab.

Bone Metastases in CRPC: Prognostic for Survival

May 17th 2015

Biomarkers Indicative of Bone Lesions in Prostate Cancer

May 17th 2015